Navigation Links
Obstetrics and Gynecology Publishes Data From Pivotal Phase 3 LYSTEDA Study
Date:10/6/2010

considered meaningful to women.  This latter point was further demonstrated by significant improvements in limitations in social or leisure and physical activities, and work inside or outside the home in women receiving LYSTEDA compared with those receiving placebo," stated Andrea Lukes, MD, MHSc, lead study investigator, Carolina Women's Research and Wellness Center.  "LYSTEDA offers clinicians a first-line, non-hormonal treatment option for women with cyclic heavy menstrual bleeding."

"We are pleased to present these data that add to the existing body of evidence demonstrating the safety and efficacy of LYSTEDA in the treatment of cyclic heavy menstrual bleeding," said Edward A. Trott, MD, Vice President of Medical Affairs, Ferring Pharmaceuticals Inc. "Women in the study experienced a significant reduction in menstrual blood loss, as early as the first cycle of use, which was maintained throughout all treatment cycles.  In addition to the reduction in monthly blood loss, there was a statistically significant improvement in the health-related quality-of-life parameters for social, leisure and physical activities."

LYSTEDA's Unique Mechanism of Action

LYSTEDA works to slow the breakdown of clots thereby reducing cyclic HMB.  LYSTEDA does not cause clots and has no effect on clotting factors or platelet function.*

In the fibrinolytic pathway, tissue plasminogen activator binds with plasminogen, cleaving it to the active form of the enzyme plasmin.  This activated enzyme binds the fibrin mesh that holds a clot together and cleaves it, allowing the clot to break apart.  Many HMB patients have higher levels of plasminogen activators than those with normal bleeding.  For those patients, fibrinolysis breaks down the normal fibrin matrix in the endometrium, causing a more rapid breakdown of the blood clot and excessive blood loss.  LYSTEDA binds to the fibrin-binding site of plasmin, preventing it
'/>"/>

SOURCE Ferring Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Boston Scientifics Urology/Gynecology Products Featured in Studies at Global Congress
2. Siemens Healthcare Diagnostics Publishes Global Trade Item Numbers (GTINs) for its Entire U.S. Product Line to the GHX Health ConneXion(SM) Data Pool
3. The ASCO Post Publishes Multiple Perspectives on Outcome of ODAC Meeting Regarding Bevacizumab in Advanced Breast Cancer
4. The New England Journal of Medicine Publishes Results of Landmark CREST Study, Showing Similar Positive Outcomes for Abbotts Carotid Stent System and Surgery
5. The Lancet publishes new data demonstrating superior efficacy of Victoza(R) (liraglutide [rDNA] injection) compared to Januvia(R) (sitagliptin) in the treatment of type 2 diabetes
6. BioTrends Publishes New Report Exploring Treatment Patterns for Anemia Across a Variety of Physician Specialties
7. NexBio(R) Publishes Two Articles Showing DAS181 (Fludase(R)*) Potently Inhibits Pandemic Influenza A(H1N1) and NAI-Resistant Influenza Viruses
8. BIA Publishes White Paper: ISO 9000 Role in Document Review, Emphasizes Quality Equals Defensibility
9. United States Patent and Trademark Office Publishes Stemedicas Patent Application for the Treatment of Diabetic Retinopathy
10. The Lancet Publishes Direct Comparison Study Between Liraglutide and Exenatide
11. The Lancet Publishes Two-Year Results of Abbotts Fully Bioabsorbable Drug Eluting Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2014)... PLEASANTON, Calif. , July 21, 2014 ... leader in device-based mechanical circulatory support therapies to save, ... will report its operating results for the second quarter ... The company will hold a conference call to ... all interested parties, at 1:30 p.m., Pacific Daylight Time ...
(Date:7/21/2014)... PORTLAND, Oregon , July 21, 2014 /PRNewswire/ ... by Allied Market Research titled, "Global biosimilars/follow-on-biologics market ... Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, ... that the global biosimilars market would reach $35 ... in 2013. Deeper penetration with clearer regulatory pathways ...
(Date:7/21/2014)... By order of the U.S. Bankruptcy Court, Tiger Group,s Remarketing ... optical equipment, designer eyeglass frames, and other assets of ... LLC. Online bidding opens July 21 at ... style, on July 28 beginning at 10:30 a.m. (ET). Previews ... 25 th and 26 th at 12 locations ...
Breaking Medicine Technology:Thoratec Schedules Second Quarter Conference Call, Webcast 2Biosimilars/Follow-on-Biologics Market is Expected to Reach $35 Billion, Globally, by 2020 2Biosimilars/Follow-on-Biologics Market is Expected to Reach $35 Billion, Globally, by 2020 3Biosimilars/Follow-on-Biologics Market is Expected to Reach $35 Billion, Globally, by 2020 4Auction Set For Assets Of National Optical Services Company 2
... Manufacturing - Has Potential to Address Gaps in Global ... World Health Organization Meeting on Evaluation of Pandemic Influenza ... NVAX ) announced favorable results from the second ... its pandemic influenza virus-like particle (VLP) vaccine candidate. ...
... Scientists announced today the,publication of a landmark peer-reviewed ... Stem Cell Journal which outlines the long term ... neural stem cells for the,treatment of Parkinson,s disease. ... FACS, "We have documented the first successful adult,neural ...
Cached Medicine Technology:Novavax Presents Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program at World Health Organization Conference 2Novavax Presents Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program at World Health Organization Conference 3Novavax Presents Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program at World Health Organization Conference 4Novavax Presents Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program at World Health Organization Conference 5Groundbreaking Paper Publishes Long Term Results of a Successful Phase I Clinical Trial Using Autologous Neural Stem Cells to Treat Parkinson's Disease 2Groundbreaking Paper Publishes Long Term Results of a Successful Phase I Clinical Trial Using Autologous Neural Stem Cells to Treat Parkinson's Disease 3
(Date:7/22/2014)... 22, 2014 Cumberland Pediatric Dentistry ... dental experience that values anxiety-free dental care for children, ... for a child's dental care. , The orthodontic ... care to infants, adolescents, adults and those with special ... physical disability, or require unique care, such as cleft ...
(Date:7/22/2014)... 2014 NOVAtime Technology, Inc. ( ... and Attendance / Workforce Management solutions, announced today ... customer since 2007, has upgraded to NOVAtime ... state-of-the-art, web-based time and attendance / workforce management ... is a human services agency that provides support ...
(Date:7/22/2014)... Colorado (PRWEB) July 22, 2014 CareTouch ... called CareTouch in the Community . CareTouch employees ... year, and provide hands-on support in line with their ... improve their health. The program’s first cause is Hike ... Hospice. , On Sunday, September 14, the CareTouch ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 The ... Group are now offering robotic assisted laser therapy ... best solutions for men and women suffering from ... procedure they now offer Follicular Unit Extraction (FUE) ... medical robot. With this new technology, their doctors ...
(Date:7/22/2014)... 22, 2014 The physical demands of ... plyometrics, powerlifting, gymnastics, kettleball lifting, calisthenics, and strongman exercises ... Jason Sobzcak, co-owner of CrossFit East Cobb, ... because extreme workouts like these require high quality supplementation. ... I need to take in about 160 grams of ...
Breaking Medicine News(10 mins):Health News:Cumberland Pediatric Dentistry and Orthodontics of Clarksville Welcomes Dr. Peter Wojtkiewicz, Pediatric Orthodontist 2Health News:Cumberland Pediatric Dentistry and Orthodontics of Clarksville Welcomes Dr. Peter Wojtkiewicz, Pediatric Orthodontist 3Health News:Lutheran Services in Iowa Upgrades to NOVAtime 4000 Time and Attendance / Workforce Management Solution; Benefits from Labor Costing Functionality 2Health News:Lutheran Services in Iowa Upgrades to NOVAtime 4000 Time and Attendance / Workforce Management Solution; Benefits from Labor Costing Functionality 3Health News:CareTouch is a Peak Sponsor for the 9th Annual Hike for Hospice in Morrison, Colorado 2Health News:WeGrowHair.com/PAI Medical Group Introduces Robotic Assisted Laser Therapy to Treat Hair Loss 2Health News:CrossFit East Cobb Fuels Their Intense Workouts with All-Natural EnergyFirst Supplements 2Health News:CrossFit East Cobb Fuels Their Intense Workouts with All-Natural EnergyFirst Supplements 3
... to be a major complication of diabetes, despite the ... amputations are currently performed among the diabetic population. ... in the retinas of about 900 diabetic patients who ... All were followed for 20 years to assess how ...
... new study shows hydrotherapy, or water exercise, may improve strength ... Australia studied more than 100 patients with osteoarthritis who were ... The first group exercised three times a week in a ... third did not exercise at all. Both the water and ...
... Chronic lung disease is a primary long-term complication among ... are at greater risk for pulmonary hypertension and impaired ... risk of developing neurological problems. ,A new ... benefit from treatment with inhaled nitric oxide. ,Researchers ...
... pain, pelvic pressure, frequent urination or abnormal periods, uterine ... found in the uterus and can// range in size ... or larger. Now, there’s an improvement to uterine fibroid ... choice for many women. ,Sabrina Figueroa considers herself ...
... back pain is when symptoms have lasted for less ... program that includes group classes, exercise sheet// handouts, and ... their back pain. ,Researchers from Indiana University ... low back pain. The program focuses on boosting confidence ...
... years, Keith Black, M.D., from Cedars-Sinai Medical Center in Los ... cancer. While his research moves forward, he’s helping patients ... tumor vaccine. Dr. Black says brain tumors ... the immune system could use to recognize the tumor. By ...
Cached Medicine News:Health News:Uterine Fibroid Embolization Gaining Popularity 2Health News:New vaccine for brain cancer 2
Compact, bench-top analyser with minimal water volume requirements and easy waste management....
Compact benchtop clinical chemistry system...
... 350 Chemistry System offers easy operation, maintenance, and ... STAT, or back-up to the powerful VITROS 5,1 ... the job done right the first time. Its ... are efficient, dependable, and easy-to-use. The VITROS 350 ...
Meet Galileo, the best reason to move to automation; the best way to upgrade your capabilities....
Medicine Products: